Results from Gene ID Studies Could Lead to New Dxs for Genomic Health

Studies presented at ASCO’s annual meeting could lead to the development of two new diagnostics tests, expanding the indication of Genomic Health’s Oncotype DX technology into gauging treatment benefit with Erbitux in colorectal cancer and Taxotere in breast cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.